TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2645202 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR